NDAORALCAPSULEPriority Review
Approved
Feb 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 41m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATROMID-S (clofibrate) is an oral fibrate class lipid-lowering agent approved in 1967 for the treatment of dyslipidemia and related metabolic disorders. It works by modulating lipid metabolism to reduce triglycerides and cholesterol levels. The drug represents a legacy therapeutic from the early era of cardiovascular pharmacotherapy.
LOE Approaching
As an aging product approaching loss of exclusivity with moderate competitive pressure (30), team sizes are likely lean and focused on managed decline or niche positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ATROMID-S offers minimal career momentum; the zero linked job count and LOE-approaching lifecycle indicate this is a maintenance or legacy portfolio assignment rather than a growth opportunity. Best suited for professionals seeking stable, low-pressure roles managing established therapies or transitioning to newer programs.
Product Manager (Specialty/Legacy)
Worked on ATROMID-S at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.